pemetrexed

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Thymidylate synthase inhibitor, THF dehydrogenase inhibitor

Related drugs:

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	pemetrexed Resistant: A2 - Guideline pemetrexed Resistant : A2	pemetrexed Resistant: A2 - Guideline pemetrexed Resistant : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Mesothelioma	No biomarker	Mesothelioma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Head and Neck Cancer	No biomarker	Head and Neck Cancer	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	carboplatin + pemetrexed Sensitive: B - Late Trials carboplatin + pemetrexed Sensitive : B	carboplatin + pemetrexed Sensitive: B - Late Trials carboplatin + pemetrexed Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: B - Late Trials cisplatin + pemetrexed Sensitive : B	cisplatin + pemetrexed Sensitive: B - Late Trials cisplatin + pemetrexed Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2	pemetrexed Sensitive: C2 – Inclusion Criteria pemetrexed Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	carboplatin + camrelizumab + pemetrexed Sensitive: C3 – Early Trials carboplatin + camrelizumab + pemetrexed Sensitive : C3	carboplatin + camrelizumab + pemetrexed Sensitive: C3 – Early Trials carboplatin + camrelizumab + pemetrexed Sensitive : C3
ALK V3b	Non Small Cell Lung Cancer	ALK V3b	Non Small Cell Lung Cancer	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3
ALK V3a	Non Small Cell Lung Cancer	ALK V3a	Non Small Cell Lung Cancer	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3	pemetrexed Resistant: C3 – Early Trials pemetrexed Resistant : C3
OGG1 S326C	Lung Adenocarcinoma	OGG1 S326C	Lung Adenocarcinoma	carboplatin + pemetrexed Sensitive: C3 – Early Trials carboplatin + pemetrexed Sensitive : C3	carboplatin + pemetrexed Sensitive: C3 – Early Trials carboplatin + pemetrexed Sensitive : C3

pemetrexed

Associations
(58)

Associations
(58)

pemetrexed

Associations(58)

Associations(58)

Associations
(58)

Associations
(58)